Physician profile
Thomas G Sinclair
NPI 1841230430
$325.53
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $11.60 · 2022: $24.35.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $102.08 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $101.43 | 2019 | |
| Smith+Nephew, INC. | $38.96 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $24.35 | 2022 | |
| Merck Sharp & Dohme LLC | $18.74 | 2019 | |
| Lilly USA, LLC | $15.09 | 2019 | |
| Tactile Systems Technology INC | $13.28 | 2019 | |
| Integra Lifesciences Corporation | $11.60 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sinclair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.